InvestorsHub Logo
Followers 8
Posts 1894
Boards Moderated 0
Alias Born 05/05/2016

Re: Whalatane post# 15106

Wednesday, 03/16/2022 2:38:19 PM

Wednesday, March 16, 2022 2:38:19 PM

Post# of 17590



..that my wife ( who actually has LN patients ) has had with those in her field ..Nephrology

Sorry, your appeal to authority is meaningless, you could claim that your wife is the long lost Russian Empress... this is a public forum, with many individuals and many agendas (maybe even simple entertainment, like gadflies for example).

In any case, unless your wife is working in an academic medical institution (an assertion you did NOT make), doing statistical research on patient compliance, any "data" now is too early and inadequate for extrapolation to any conclusions.

Why the drop of ZZ ?

Not understood at this time, nor do we know if the "pattern" is going to hold up over the next year or so.

As far as the unfortunate side effects, that's a reality for many patients with a variety of diseases. Each patient makes his/her own decisions if the benefit is worth it. At this point alternatives are inferior to Lupkynis, and LN does not spontaneously disappear. The consequences of not treating the disease is catastrophic.

So up to 30% of all new scripts written fail to get renewed ....and thats not a problem for U ?

More of a problem for patients! From my perspective, 70% DOES get renewed, and as the total number of scripts increases, 70% of more scripts is more renewals and more revenue.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News